Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RMC-6291 · 2 trials · 9 indications
Incidence and severity of treatment-emergent Adverse Events (AEs) and serious AEs and clinically significant changes in laboratory values, ECGs and vital signs
Number of participants with dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Subprotocol A: KRAS G12C-Mutated Solid Tumors | EXPERIMENTAL | RMC-6291 (BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W) |
| Subprotocol B: RAS-mutated NSCLC | EXPERIMENTAL | RMC-6236 (QD) and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W) |
| Subprotocol C: RAS G12D-mutated NSCLC | EXPERIMENTAL | RMC-9805 (QD or BID), RMC-6236 (QD), and Pembrolizumab (Q3W) with or without Chemotherapy (Q3W). |
| Subprotocol D: RAS G12D-mutated NSCLC | EXPERIMENTAL | RMC-9805 (QD) |
| RMC-6291 | EXPERIMENTAL | Dose Escalation and Dose Expansion |
| Name | Type | Description |
|---|---|---|
| RMC-6291 | DRUG | Oral tablet |
| RMC-6236 | DRUG | Oral tablet |
| Pembrolizumab | DRUG | IV Infusion |
| Cisplatin | DRUG | IV Infusion |
| Carboplatin | DRUG | IV Infusion |
| Pemetrexed | DRUG | IV infusion |
| RMC-9805 | DRUG | Oral Tablet |
Inclusion criteria: All Patients (unless otherwise noted): * ≥ 18 years of age * ECOG PS is 0 to 1 * Adequate organ function as outlined by the study * Received prior standard therapy appropriate for tumor type and stage * Must have pathologically documented, locally advanced or metastatic KRAS G1...
RMC-6291 is an investigational small molecule being studied for the treatment of KRAS G12C-mutant solid tumors, including Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), and Pancreatic Ductal Adenocarcinoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
RMC-6291 targets the KRAS G12C mutation, a specific genetic alteration found in certain cancers. It is designed to inhibit the activity of this mutant protein, which is involved in tumor growth. The drug is being evaluated in patients with advanced solid tumors harboring this mutation.
RMC-6291 is being developed by Revolution Medicines, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RVMD. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with KRAS G12C-mutated cancers.
RMC-6291 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing trials are designed to assess its safety, tolerability, and preliminary efficacy in patients with advanced KRAS G12C-mutant solid tumors.
RMC-6291 is being studied in two Phase 1 clinical trials. The first, NCT05462717, is a dose escalation and expansion study of RMC-6291 monotherapy in advanced KRAS G12C-mutant solid tumors. The second, NCT06162221, evaluates RAS(ON) inhibitors in patients with advanced RAS-mutated NSCLC. Both trials are active.
RMC-6291 is a RAS(ON) inhibitor, a class of drugs that target the active, GTP-bound form of RAS proteins. It specifically targets the KRAS G12C mutation. The drug is being studied alone and in combination with other RAS(ON) inhibitors in clinical trials for advanced solid tumors.